Analysts raise questions over quality & length of Johnson & Johnson's medical technology pipeline
This article was originally published in Clinica
Executive Summary
Johnson & Johnson's medical devices and diagnostics (MD&D) operations' years of robust growth are drawing to a close: that was the impression that emerged from the group's investor meeting on September 6.